Cardio Diagnostics Reports $1.79M Net Loss on Just $2.68K Revenue in Q1
CDIO sits 60% above its 52-week low of $0.97.
Summary
Cardio Diagnostics Holdings, Inc. reported first-quarter 2026 results with extremely low revenue of $2.68K and a significant net loss of $1.79 million, leading to a diluted loss per share of ($0.63). This follows the company's annual report in March 2026, which already highlighted ongoing substantial net losses and a declining cash balance, often funded through dilutive at-the-market offerings. Despite a 185.1% year-over-year revenue increase, the absolute revenue figure remains negligible, while the net loss increased by 9.4% year-over-year, indicating continued substantial cash burn relative to its micro-cap valuation. A professional trader would view these results as a confirmation of the company's ongoing financial challenges and will be watching for any signs of meaningful revenue scaling or a reduction in operating losses.
At the time of this announcement, CDIO was trading at $1.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6M. The 52-week trading range was $0.97 to $7.91. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.